je.st
news
First Presentation of Data for Pembrolizumab, Mercks Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024) Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
cell
presentation
Category:Biotechnology and Pharmaceuticals